The UAE has become one of the first countries to approve Eli Lilly's once-daily oral obesity pill, Foundayo (orforglipron), a GLP-1 receptor agonist that mimics natural hormones to regulate appetite.

Results from the most comprehensive study to date on the active ingredient orforglipron, published in The Lancet, indicate that a new weight-loss tablet could significantly help patients with type 2 diabetes.

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.

Eli Lilly is preparing to release orforglipron, a new once-daily GLP-1 pill, which has shown an average of 15-20 pounds of weight loss in clinical trials for people with diabetes.

Eli Lilly has committed an additional US$3 billion investment in China over the next decade to enhance its local supply chain and manufacturing capabilities, anticipating approval for its drug orforglipron.